Abstract
Radioimmunoscintigraphy (RIS) with 131I labeled OC-125 F(ab')2 monoclonal antibody fragments was prospectively studied in 43 women for primary diagnosis and follow up of ovarian cancer. Total body planar photoscans with a scintillation camera were performed one to seven days after antibody application and results were compared with operation and or CT examination. By the region of interest technique the tumor to non tumor tissue ratio (T/N) was calculated in vivo. Sensitivity in primary diagnosis was 100% (10/10), specificity 33% (1/3). For local recurrency, sensitivity was 86% (19/22), for metastatic loci 80% (17/21). Specificity was 75% and 50%. T/N ratio was in the rage from 1.3 to 2.8. Sensitivity for ovarian cancer is high in primary diagnosis and follow up. By the region of interest technique it is possible to detect small recurrencies and to presume peritoneal carcinosis. Antibody accumulations in diseases different from ovarian cancer however diminish specificity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin NB, Knapp RC (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68:1331–1337
Baum RP, Maul FD, Senekowitsch S, Chatal JF, Saccavini JC, Lorenz M, Happ J, Berthold F, Kriegel H, Hör G (1986) Radioimmunoscintigraphy and Radioimmunotherapy with monoclonal antibodies (19-9/anti-CEA and OC 125). In: Höfer R, Bergmann H, (eds) Radioaktive Isotope in Klinik und Forschung, Gastein 17, 443–447
Biersack HJ, Bockisch A, Oehr P, Knoblich A, Hartlapp J, Blitz H, Jaeger N, Bellmann O, Vogel J, Björklund B, Taylor-Papadimitriou J, Winkler C (1986) Clinical results of immunoscintigraphy in a variety of malignant tumors with special reference to immunhistochemistry. J Nucl Med 25:167–171
Buchegger F, Halpern SE, Sutherland RM, Schreyer M, Mach JP (1986) In vitro and in vivo tumor models for studies of distribution of radiolabelled monoclonal antibodies and fragments. J Nucl Med 25:207–9
Burchiel SW, Khaw BA, Rhodes BA, Smith TW, Haber E (1982) Immunopharmacokinetics of radiolabeled antibodies and their fragments. In: Burchiel SW, Rhodes BA (eds) Tumour imaging. The radiochemical detection of cancer. Masson, Paris, pp 125–139
Chatal JF, Saccavini JC, Fumoleau P (1987) Immunscintigraphy of gynecological carcinomas with I131-Oc125-F(ab')2 monoclonal antibody. J Nucl Med 26:149–190
Davis HM, Zurawsky VR, Bast RC, Klug TL (1986) Characterization of the CA 125 Antigen associated with human epithelial ovarian carcinomas. Cancer Res 46:6143–6148
Davis OJ, Davis ER, Howe K, Jackson PC, Pitcher EM, Sadowsky KS, Stirrat GM, Sunderland CA (1985) Radioniclide immaging of ovarian tumours with 123-labeled monoclonal antibody (NDOG2) directed against placental alkaline phosphatase. Br J Obstet Gynaecol 92:277–286
Deland FH, Goldenberg DM (1985) Diagnosis and treatment of neoplasms with radionuclide-labeled antibodies. Semin Nucl Med 15:2–11
Dhokia B, Canney PA, Pectasides D, Munro AJ, Moore M, Wilkinson PM, Self C, Epenetos AA (1986) A new immunoassay using monoclonal antibodies HMFG1 and HMFG2 together with an existing marker CA125 for serological detection and management of epithelial ovarian cancer. Br J Cancer 54:891–895
Epenetos AA, Carr D, Johnson PM (1986a) Antibody-guided radiolocalisation of tumours in patients with testicular or ovarian cancer using two radioiodinated monoclonal antibodies to placental alkaline phosphatase. Br J Radiol 59:117–125
Epenetos AA, Snook D, Durbin H, Johnson PM, Taylor-Papadimitriou J (1986b) Limitations of radiolabeled monoclonal antibodies for localisation of human neoplasms. Cancer Res 46:3183–3191
Goldenberg DM, Nimmon CC, DeLand FH, Kim EE (1978) Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localisation of diverse cancers by external photoscanning. New Engl J Med 298:1384–8
Goldenberg DM, Kim EE, Deland FH, Bennet S, Primus FJ (1980) Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen. Cancer Res 40:2894–2992
Granowska M, Nimmon CC, Britton KE (1986) Immunoscintigraphy of ovarian cancer by means of HMFG2 monoclonal antibody. In: Winkler C (ed) Nuclear Medicine in Clinical Oncology—Current Status and Future Aspects, Springer, Berlin Heidelberg New York, pp 171–176
Halsall AK, Fairweather DS, Bradwell AR, Blackburn JC, Dykes PW, Howell A, Reeder A, Hine KR (1981) Localisation of malignant germ-cell tumours by external scanning after injection of radiolabelled anti-alpha-fetoprotein. Br Med J 283:942–944
Hnatowich DJ, Griffin TW, McGann J, Ruskowsky M, Strahan S, Hunter R, Doherty PW (1986) Radioimmunodetection of ovarian and other tumors in patients using indium labeled OC-125 antibody; a comparison with the 19-9 antibody. In: proceedings of ASCO 5:120
Jackson PC, Pitcher EM, Davies JO, Davies ER, Sadowsky CS, Staddon GE, Stirrat GM, Sunderland CA (1985) Radionuclide imaging of ovarian tumours with a radiolabelled (J123) monoclonal antibody (NDOG2). Eur J Nucl Med 11:22–28
Kabawat SE, Bast RC, Welch WR, Knapp CR, Colvin RB (1983) Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens on human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol 79:98–104
Mach JP, Carrel S, Forni N, Ritschard J, Donath A, Alberto P (1980) Tumor localisation of radiolabeled antibodies against carcinoembryonic antigen in patients with carcinoma. New Engl J Med 303:5–10
Neuberger MS, Williams GT, Mitchell EB, Jouhal SS, Flanagan JG, Rabbitts TH (1985) A hapten-specific chimaeric IgE antibody with human physiological effector function. Nature 314:268–270
Pansini F, Bellinazi A, Rainaldi V, Santoinemma M, Lenzi B, Jacobs M, Mollica G, Bagni B (1986) Serum CA 125 in ovarian pathology and its variation in ovarian carcinoma after integrated therapy. Gynecol Obstet Invest 21:47–51
Pressman D, Korngold L (1953) The in vivo localisation of anti-Wagner osteogenic sarcoma antibodies. Cancer 6:619–22
Van Nagell JR, Kim E, Casper S, Primus FJ, Bennet S, DeLand FH, Goldenberg DM (1980) Radioimmunodetection of primary and metastatic ovarian cancer using radiolabeled antibodies to carcinoembryonic antigen. Cancer Res 40:502–506
Yerushalmy J (1947) Statistical problems in assesing methods of medical diagnosis, with special reference to X-ray techniques. Public Health Reports-US 62:1432–49
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Barzen, G., Carl Mayr, A., Langer, M. et al. Radioimmunoscintigraphy of ovarian cancer with 131-iodine labeled OC-125 antibody fragments. Eur J Nucl Med 15, 42–48 (1989). https://doi.org/10.1007/BF00253598
Issue Date:
DOI: https://doi.org/10.1007/BF00253598